Italian pharmaceutical company buys rights to immunotherapy from Sanofi
Av Enjaymo (sutimlimab) is a biologic drug that is the only approved treatment for cold agglutinin disease. On Friday, Recordati announced that the company is acquiring the global rights for the drug from France's Sanofi for 825 million US dollars.
– This transaction is in-line with our broader strategy, reaffirms our commitment to the Rare Diseases space and is complementary to our oncology portfolio, says Rob Koremans, Chief Executive Officer of Recordati, in a press release.
Recordati, headquartered in Milan, Italy, is present in 150 countries. At the end of 2023, the company had 4,450 employees and had consolidated revenue of € 2,082.3 million.
Artikeln är en del av vårt tema om News in English.